Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) major shareholder Braden Michael Leonard bought 150,000 shares of Satsuma Pharmaceuticals stock in a transaction dated Monday, November 21st. The stock was acquired at an average price of $0.71 per share, for a total transaction of $106,500.00. Following the completion of the acquisition, the insider now owns 150,000 shares in the company, valued at $106,500. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Braden Michael Leonard also recently made the following trade(s):
- On Monday, November 14th, Braden Michael Leonard bought 5,608,306 shares of Satsuma Pharmaceuticals stock. The stock was acquired at an average price of $0.69 per share, for a total transaction of $3,869,731.14.
Satsuma Pharmaceuticals Stock Performance
Satsuma Pharmaceuticals stock traded up $0.03 during trading hours on Thursday, hitting $0.76. The company had a trading volume of 1,469,647 shares, compared to its average volume of 1,958,160. The firm has a market cap of $25.15 million, a P/E ratio of -0.38 and a beta of 0.42. Satsuma Pharmaceuticals, Inc. has a 1 year low of $0.59 and a 1 year high of $8.08. The company has a 50-day moving average price of $4.87 and a two-hundred day moving average price of $4.63.
Institutional Investors Weigh In On Satsuma Pharmaceuticals
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the stock. LADENBURG THALM/SH SH reduced their target price on shares of Satsuma Pharmaceuticals to $3.00 in a report on Thursday, November 17th. HC Wainwright dropped their price target on shares of Satsuma Pharmaceuticals from $18.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, November 15th. SVB Leerink cut shares of Satsuma Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 15th. Jonestrading cut shares of Satsuma Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 16th. Finally, Mizuho cut shares of Satsuma Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $13.00 to $2.00 in a research note on Tuesday, November 15th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $7.40.
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device.
- Get a free copy of the StockNews.com research report on Satsuma Pharmaceuticals (STSA)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.